AMINA NIASSE
New York (Reuters) -The online weight loss company NOOM has begun providing a combination of a small amount of WEGOVY for a small amount of Novo Nordisk for mass production of on-demand pharmaceuticals.
NOOM will provide a composite semi -glue tide version, an active ingredient of Wegovy and Diabetes Drug Ozempic as part of a personalized program for patients.
The next -generation demand for very effective but expensive weight loss drugs has been sold in NOOM and rival remote health sites, including HIMS & HERS, Weightwatchers and RO for the past two years.
Taking a small amount of weight loss drug, sometimes a small amount of weight loss drugs, also known as microcri has gained popularity due to the high cost and side effects of medicines.
Hundreds of less than branded pharmaceuticals are a doctor and pharmacy version based on Semaglutide or Tirzepatide, the main component of Eli Lilly, the competitor of Eli Lily’s rival Jeff Bound. You can access.
However, the FDA is on May 22, the shortage and sunset deadline for the complex version of Wegovy.
NOOM offers a composite semagluide at a starting price of $ 149 per first month. According to the NOVO and Lilly websites, the cost of 2.5 millimeter Wegovy or Zepbound is $ 349.
Analysts said that a telemedicine company should pivot to use branded medicines to survive after weight watchers apply for bankruptcy.
JEFREY EGLER, the chief medical officer of NOOM, said that the provider would determine whether the patient needed less dosage due to concerns about camouflage side effects.
NOOM CEO Geoff Cook said that this action would not collide with the regulations. Cook said, “There are personalized people and have always been personalized exceptions.
Novo Nordisk says it’s illegal to create or sell semagluide copies in the United States with rare exceptions.
A spokesman for Novo Nordisk said in a statement, “As the FDA warned, the complexes are inevitable by selling knock -off three light drugs that have been changed to manipulation, unnecessary, and the excuse for transfer and ingredients.”
dosage
According to NOOM’s documents, personalized approaches can begin with half of the typical starter 0.25 milligram doses of WEGOVY, and gradually increase to about half of the maximum FDA approval capacity over 20 weeks.
